Results 181 to 190 of about 12,412 (210)

Efficacy and safety of secukinumab in patients with active psoriatic arthritis at Week 16 and up to 52 weeks: Results from a Phase III, randomized, double-blind, placebo-controlled bridging study in China. [PDF]

Chin Med J (Engl)
Leng X, Liu Y, Tang L, Sun L, Li J, Hu J, Li H, Ye S, Wu L, Duan X, Liu H, Li T, Wang Y, Bustamante M, Kaur S, Fu R, Tian Y, Yang J, Pascale P, Zeng X.   +19 more
europepmc   +1 more source

Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. [PDF]

Cureus
Abdullah A, Polus L.
europepmc   +1 more source

Acute erythrodermic psoriasis complicated by systemic capillary leak syndrome following secukinumab therapy: a case report. [PDF]

Front Immunol
Xu R, Gao X, Zhang L.
europepmc   +1 more source

A Retrospective Review of Real-World Patterns of Biologic Use in Dermatology Across Metropolitan, Regional and Rural Settings. [PDF]

Australas J Dermatol
Abeysekera N, Sibanda K, Park C, Griffin J, Wagner G, Banney L.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Secukinumab

Reactions Weekly
  +20 more sources

Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab.

Journal of Crohn's and Colitis, 2018
Secukinumab is an anti-IL 17A monoclonal antibody currently licensed for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Reyes Serrano Giménez
exaly   +2 more sources

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. [PDF]

Rheumatology, 2019
Objectives:To evaluate the effect of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, on efficacy, imaging outcomes, and safety through 4 years (208 weeks) in patients with ankylosing spondylitis.
Atul Deodhar, Denis Poddubnyy, Paul Emery   +2 more
exaly   +2 more sources

Secukinumab

Reactions Weekly, 2020
  +7 more sources